| HER2-low breast cancer: pathological and clinical landscape P Tarantino, E Hamilton, SM Tolaney, J Cortes, S Morganti, E Ferraro, ... Journal of Clinical Oncology 38 (17), 1951-1962, 2020 | 625 | 2020 |
| Recent advances in triple negative breast cancer: the immunotherapy era A Marra, G Viale, G Curigliano BMC medicine 17, 1-9, 2019 | 377 | 2019 |
| Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies A Marra, D Trapani, G Viale, C Criscitiello, G Curigliano NPJ breast cancer 6 (1), 54, 2020 | 258 | 2020 |
| Evolution of low HER2 expression between early and advanced-stage breast cancer P Tarantino, S Gandini, E Nicolò, P Trillo, F Giugliano, P Zagami, ... European Journal of Cancer 163, 35-43, 2022 | 153 | 2022 |
| Are all cyclin-dependent kinases 4/6 inhibitors created equal? A Marra, G Curigliano NPJ breast cancer 5 (1), 27, 2019 | 115 | 2019 |
| Breast implant-associated anaplastic large cell lymphoma: a comprehensive review A Marra, G Viale, SA Pileri, G Pravettoni, G Viale, F De Lorenzi, F Nolè, ... Cancer treatment reviews 84, 101963, 2020 | 104 | 2020 |
| The experience on coronavirus disease 2019 and cancer from an oncology hub institution in Milan, Lombardy Region D Trapani, A Marra, G Curigliano European journal of cancer 132, 199-206, 2020 | 76 | 2020 |
| Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers NJ Choudhury, A Marra, JSY Sui, J Flynn, SR Yang, CJ Falcon, ... Journal of Thoracic Oncology 18 (4), 463-475, 2023 | 67 | 2023 |
| Seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2 A Marra, D Generali, P Zagami, V Cervoni, S Gandini, S Venturini, ... Annals of Oncology 32 (1), 113-119, 2021 | 65 | 2021 |
| Adjuvant and neoadjuvant treatment of triple-negative breast cancer with chemotherapy A Marra, G Curigliano The Cancer Journal 27 (1), 41-49, 2021 | 64 | 2021 |
| Is there an interplay between immune checkpoint inhibitors, thromboprophylactic treatments and thromboembolic events? Mechanisms and impact in non-small cell lung cancer patients F Nichetti, F Ligorio, E Zattarin, D Signorelli, A Prelaj, C Proto, G Galli, ... Cancers 12 (1), 67, 2019 | 55 | 2019 |
| Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature F Sabbatino, A Marra, L Liguori, G Scognamiglio, C Fusciello, G Botti, ... Journal for ImmunoTherapy of Cancer 6 (126), 2018 | 51 | 2018 |
| Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomas DS Ross, KA Devereaux, C Jin, DYT Lin, Y Zhang, A Marra, V Makker, ... Modern Pathology 35 (7), 962-971, 2022 | 43 | 2022 |
| The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance DR Caswell, P Gui, MK Mayekar, EK Law, O Pich, C Bailey, J Boumelha, ... Nature Genetics 56 (1), 60-73, 2024 | 41 | 2024 |
| Expression of tumor-associated antigens in breast cancer subtypes G Curigliano, V Bagnardi, M Ghioni, J Louahed, V Brichard, FF Lehmann, ... The Breast 49, 202-209, 2020 | 41 | 2020 |
| Integration of clinical sequencing and immunohistochemistry for the molecular classification of endometrial carcinoma E Rios-Doria, A Momeni-Boroujeni, CF Friedman, P Selenica, Q Zhou, ... Gynecologic oncology 174, 262-272, 2023 | 38 | 2023 |
| APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas P Selenica, A Marra, NJ Choudhury, A Gazzo, CJ Falcon, J Patel, X Pei, ... Annals of oncology 33 (12), 1284-1295, 2022 | 38 | 2022 |
| Long-term disease-free survival in surgically-resected oral tongue cancer: a 10-year retrospective study A Marra, M Violati, F Broggio, C Codecà, M Blasi, A Luciani, S Zonato, ... Acta Otorhinolaryngologica Italica 39 (2), 84, 2019 | 38 | 2019 |
| The clinical behavior and genomic features of the so-called adenoid cystic carcinomas of the solid variant with basaloid features CJ Schwartz, E Brogi, A Marra, AFDC Paula, GJ Nanjangud, EM da Silva, ... Modern Pathology 35 (2), 193-201, 2022 | 37 | 2022 |
| Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives A Marra, S Chandarlapaty, S Modi Nature Reviews Clinical Oncology 21 (3), 185-202, 2024 | 35 | 2024 |
Paolo TarantinoDana-Farber Cancer Institute, Harvard Medical SchoolE-mail megerősítve itt: dfci.harvard.edu